SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced a multi-year strategic research collaboration with NVIDIA that couples Genentech’s artificial intelligence (AI) capabilities, extensive biological and molecular datasets, and research expertise with NVIDIA’s world-leading accelerated computing capabilities and AI to speed up drug discovery and development.

加利福尼亚州南旧金山-（商业线）-罗氏集团成员Genentech（SIX:RO，ROG；OTCQX:RHHBY）今天宣布与NVIDIA进行多年战略研究合作，将Genentech的人工智能（AI）功能，广泛的生物和分子数据集，以及NVIDIA世界领先的加速计算能力和AI的研究专业知识，以加速药物发现和开发。

The collaboration is designed to significantly enhance Genentech’s advanced AI research programs by transforming its generative AI models and algorithms into a next-generation AI platform, expediting the discovery and delivery of novel therapies and medicines to people..

该合作旨在通过将其生成的AI模型和算法转换为下一代AI平台，加快向人们发现和提供新疗法和药物，从而显着增强Genentech的先进AI研究计划。。

The companies will join forces to accelerate and optimize Genentech’s proprietary machine learning (ML) algorithms and models on NVIDIA DGX Cloud, which provides a training-as-a-service platform built on dedicated NVIDIA AI supercomputing and software, including NVIDIA BioNemo for generative AI applications in drug discovery..

这些公司将联合起来加速和优化Genentech在NVIDIA DGX云上的专有机器学习（ML）算法和模型，该云提供基于专用NVIDIA AI超级计算和软件的培训即服务平台，包括用于生成的NVIDIA BioNemo AI在药物发现中的应用。。

NVIDIA will share its computing expertise with Genentech’s teams of computational scientists with the goal of optimizing and scaling Genentech’s models, and in that process, may improve or enhance NVIDIA’s platforms.

NVIDIA将与Genentech的计算科学家团队分享其计算专业知识，目的是优化和扩展Genentech的模型，在此过程中，可以改进或增强NVIDIA的平台。

“By harnessing the power of AI models and algorithms, with our unique data and experiments, we're unlocking scientific discoveries with incredible speed and generating insights at an unprecedented scale,” said Aviv Regev, EVP and head of Genentech Research and Early Development (gRED). “Bringing science and technology together has always been a foundation of biomedical breakthroughs at Genentech.

EVP和基因泰克研究与早期发展（Genentech Research and Early Development）负责人Aviv Regev说：“通过利用人工智能模型和算法的力量，利用我们独特的数据和实验，我们以惊人的速度释放科学发现，并以前所未有的规模产生见解。（gRED）。“将科学技术融合在一起一直是基因泰克公司生物医学突破的基础。

We are thrilled to join forces with NVIDIA to further optimize our drug discovery and development to deliver treatments that transform people’s lives.”.

我们很高兴与NVIDIA合作，进一步优化我们的药物发现和开发，以提供改变人们生活的治疗方法。

“The greatest impact of generative AI is to revolutionize the life science and healthcare industry,” said Jensen Huang, founder and CEO of NVIDIA. “Our collaboration to create Genentech’s next-generation AI platform will dramatically accelerate the pace of drug discovery and development.”

NVIDIA的创始人兼首席执行官黄延森（Jensen Huang）说：“生成人工智能的最大影响是彻底改变生命科学和医疗保健行业。“我们与创建Genentech下一代AI平台的合作将大大加快药物发现和开发的步伐。”

The collaboration with NVIDIA complements Genentech’s AI/ML teams, which are developing and leveraging AI and ML foundational models across numerous research areas including diverse therapeutic modalities. Genentech scientists aim to glean new insights for target and drug discovery and to answer fundamental questions about human biology and disease..

与NVIDIA的合作补充了Genentech的AI/ML团队，该团队正在众多研究领域开发和利用AI和ML基础模型，包括多种治疗方式。基因泰克公司的科学家们旨在收集有关靶标和药物发现的新见解，并回答有关人类生物学和疾病的基本问题。。

The collaboration will also help accelerate Genentech’s “lab in a loop,” where extensive experimental data feeds computational models that uncover patterns and make new, experimentally testable predictions. Scientists quickly assess these predictions in the lab and the results are fed back into the models to improve the underlying computational model, allowing for iterative development of better therapies..

这种合作还将有助于加快Genentech的“循环实验室”，在该实验室中，大量的实验数据可提供发现模式并进行新的，可通过实验测试的预测的计算模型。科学家们在实验室中快速评估这些预测，并将结果反馈到模型中以改进基础计算模型，从而可以迭代开发更好的疗法。。

Activities will leverage publicly available and Genentech-proprietary data. Genentech will control the sharing of its proprietary data and NVIDIA will not have direct access to Genentech’s proprietary data unless granted by Genentech for use in a particular project during the term of that project.

活动将利用公开可用的Genentech专有数据。Genentech将控制其专有数据的共享，除非Genentech在该项目有效期内授予特定项目使用，否则NVIDIA将无法直接访问Genentech的专有数据。

Drug discovery and development is currently a lengthy, complicated, and uncertain process. Targets for novel medicines are difficult to predict, as is successfully developing a molecule as a potential therapeutic. Genentech believes that AI plays an invaluable role in revolutionizing drug development, in combination with people, science and technology, helping make it more predictable and cost-effective, boosting the success rate of R&D over the long term, and ultimately helping discover and design therapeutics to improve people’s lives..

药物发现和开发目前是一个漫长，复杂和不确定的过程。新药的目标很难预测，成功开发分子作为潜在的治疗药物也是如此。Genentech认为人工智能在药物开发革命中发挥着宝贵的作用，与人，科学和技术相结合，帮助使其更具可预测性和成本效益，长期提高研发成功率，最终帮助发现和设计改善人们生活的疗法。。

About Genentech

关于基因泰克

Founded more than 45 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California.

Genentech成立于45多年前，是一家领先的生物技术公司，发现，开发，制造和商业化药物，用于治疗严重危及生命的医疗条件的患者。该公司是罗氏集团的成员，总部设在加利福尼亚州南旧金山。

For additional information about the company, please visit http://www.gene.com..

有关公司的更多信息，请访问http://www.gene.com..